Empagliflozin vs metformin in PCOS
Research type
Research Study
Full title
The effect of empagliflozin versus metformin on hormonal, metabolic and cardiovascular risk factors in patients with polycystic ovary syndrome (PCOS) – a randomised open-label parallel study.
IRAS ID
208841
Contact name
Thozhukat Sathyapalan
Contact email
Sponsor organisation
Research & Development Department, Hull & East Yorkshire Hospitals NHS Trust
Eudract number
2016-004435-20
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
Polycystic ovary syndrome (PCOS) is a very common condition in women that may present with irregular periods, excessive hair growth on the face and body, acne and cysts in the ovaries. PCOS is also associated with increased risk of problems later in life like diabetes, high cholesterol levels and heart disease.
In this study, a medication named Empagliflozin will be tested. Empagliflozin belongs to a class of medicines known as SGLT-2 inhibitors. SGLT-2 stands for sodium glucose co-transporter 2. Empagliflozin increases the amount of glucose passed in your urine. This medicine is usually used in patients with type 2 diabetes and has led to improved blood pressure and weight loss in addition to improving blood glucose levels.
We want to give Empagliflozin to women with PCOS to see its effect on hormones related to PCOS and the risk factors for diabetes and heart disease. We will be comparing its effects to metformin (another drug for diabetes) which has already been used in PCOS with very good results.REC name
Yorkshire & The Humber - Leeds East Research Ethics Committee
REC reference
17/YH/0118
Date of REC Opinion
8 Jun 2017
REC opinion
Further Information Favourable Opinion